Drug intelligence / Profile preview

YHI-1501

Development stage: Unknown
Lead developer: Yakult Honsha
Modality: Small Molecules
Administration: Oral

Overview

YHI-1501 is an investigational small molecule metabolic agent being developed by Yakult Honsha for the treatment of hyperuricemia. It functions as a selective inhibitor of the urate transporter 1 (URAT1), a protein encoded by the SLC22A12 gene that is responsible for the reabsorption of uric acid in the proximal tubules of the kidney. By inhibiting URAT1, YHI-1501 increases the renal excretion of uric acid, thereby lowering serum uric acid levels. As of 2024, the drug is in Phase 1 clinical development in Japan, with studies evaluating its safety, tolerability, and pharmacokinetics in healthy adult subjects.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on YHI-1501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHI-1501.

Explore the full profile